Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MenACWY-CRM conjugate vaccine · 1 trial · 1 indication
Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported. Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.
The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
| Arm | Type | Description |
|---|---|---|
| rMenB+OMV | EXPERIMENTAL | Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart |
| MenACWY | EXPERIMENTAL | Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart |
| Control | ACTIVE_COMPARATOR | Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart |
| Name | Type | Description |
|---|---|---|
| Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ) | BIOLOGICAL | - |
| MenACWY-CRM conjugate vaccine | BIOLOGICAL | - |
| Japanese Encephalitis vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Healthy subjects, 18-24 years of age who provided written informed consent at the time of enrollment; * Subjects who were available for all the visits scheduled in the study; * Subjects who were in good health as determined by the outcome of medical history, physical examinati...
MenACWY-CRM conjugate vaccine is used for the prevention of meningococcal disease, meningococcal meningitis, and N. meningitidis carriage. It is an investigational vaccine being developed by Novartis AG for these infectious disease indications.
MenACWY-CRM conjugate vaccine is being developed by Novartis AG, which trades under the ticker NVS. The vaccine is currently in clinical development for the prevention of meningococcal disease and related conditions.
MenACWY-CRM conjugate vaccine is in Phase 3 clinical development. It has completed two Phase 3 trials, including a carriage trial and a persistence study, along with two earlier Phase 2 trials.
MenACWY-CRM conjugate vaccine has completed four clinical trials. These include NCT00262041 and NCT00310817 in Phase 2, and NCT00856297 and NCT01214850 in Phase 3, covering adolescents, children, and adults in multiple countries.
Yes, MenACWY-CRM conjugate vaccine is the same as the Novartis Meningococcal ACWY Conjugate Vaccine. Clinical trials refer to it by both names, with the vaccine being evaluated for safety and immunogenicity across different age groups.